JPH0321150B2 - - Google Patents

Info

Publication number
JPH0321150B2
JPH0321150B2 JP56000521A JP52181A JPH0321150B2 JP H0321150 B2 JPH0321150 B2 JP H0321150B2 JP 56000521 A JP56000521 A JP 56000521A JP 52181 A JP52181 A JP 52181A JP H0321150 B2 JPH0321150 B2 JP H0321150B2
Authority
JP
Japan
Prior art keywords
dna
hif
ifn
fragment
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56000521A
Other languages
English (en)
Japanese (ja)
Other versions
JPS56150100A (en
Inventor
Baisuman Chaaruzu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen NV
Original Assignee
Biogen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8187070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0321150(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen NV filed Critical Biogen NV
Publication of JPS56150100A publication Critical patent/JPS56150100A/ja
Publication of JPH0321150B2 publication Critical patent/JPH0321150B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y10S435/839—Bacillus subtilis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP52181A 1980-01-08 1981-01-07 Manufacture of dna order,recombination dna molecule and human interferon-like polypeptide Granted JPS56150100A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP80300079 1980-01-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP63307943A Division JP2501889B2 (ja) 1980-01-08 1988-12-07 α−インタ−フェロンを含有する薬学的組成物

Publications (2)

Publication Number Publication Date
JPS56150100A JPS56150100A (en) 1981-11-20
JPH0321150B2 true JPH0321150B2 (enExample) 1991-03-22

Family

ID=8187070

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52181A Granted JPS56150100A (en) 1980-01-08 1981-01-07 Manufacture of dna order,recombination dna molecule and human interferon-like polypeptide
JP61182054A Granted JPS62122590A (ja) 1980-01-08 1986-08-04 組替えＤＮＡ分子、これにより形質転換された宿主、およびＩＦＮ−α型ポリペプチドをコ−ドするＤＮＡ配列

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP61182054A Granted JPS62122590A (ja) 1980-01-08 1986-08-04 組替えＤＮＡ分子、これにより形質転換された宿主、およびＩＦＮ−α型ポリペプチドをコ−ドするＤＮＡ配列

Country Status (7)

Country Link
US (1) US4530901A (enExample)
JP (2) JPS56150100A (enExample)
IN (1) IN153751B (enExample)
MD (1) MD431C2 (enExample)
SU (1) SU1764515A3 (enExample)
UA (1) UA13380A (enExample)
ZA (1) ZA81103B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046221A1 (ja) * 2009-10-16 2011-04-21 学校法人立命館 インターフェロン－αモジュレーター

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
DE3176011D1 (en) * 1980-06-12 1987-04-23 Japan Found Cancer Plasmid
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4810645A (en) * 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US5399684A (en) * 1982-05-20 1995-03-21 Washington Research Foundation DNA sequences expressing mammalian alpha-1-antitrypsin
DE3220116A1 (de) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
JPS60222500A (ja) * 1983-12-19 1985-11-07 シエリング・コ−ポレ−シヨン 新規ハイブリツドインタ−フエロン
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4710465A (en) * 1984-04-19 1987-12-01 Yale University Junction-fragment DNA probes and probe clusters
SU1364343A1 (ru) * 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получени человеческого лейкоцитарного интерферона альфа-2
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US4874743A (en) * 1985-01-10 1989-10-17 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides
US5081019A (en) * 1985-01-10 1992-01-14 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides
US4950646A (en) * 1985-01-10 1990-08-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides
US4879224A (en) * 1985-01-10 1989-11-07 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
WO1986004608A1 (en) * 1985-02-05 1986-08-14 Synergen Biologicals, Inc. Metalloproteinase inhibitor sequence recombinant vector system for using same and recombinant-dna method for the manufacture of same
JPS61185189A (ja) * 1985-02-08 1986-08-18 Green Cross Corp:The 新規インタ−フエロン−α↓１ＤＮＡ配列、組み換えプラスミド及び形質転換体
US4894332A (en) * 1985-03-27 1990-01-16 Biogen, Inc. DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins
US6774283B1 (en) 1985-07-29 2004-08-10 Calgene Llc Molecular farming
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US5135868A (en) * 1985-10-25 1992-08-04 Phillips Petroleum Company Cultures of yeast of the genus Pichia altered by site selective genomic modification
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5089406A (en) * 1987-01-07 1992-02-18 Allied-Signal Inc. Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
JPH01503513A (ja) * 1987-03-02 1989-11-30 オンコゲン 血小板関連増殖調節剤
JPS6463395A (en) 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
EP0330396B1 (en) * 1988-02-26 1995-06-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI
US5605815A (en) * 1988-03-14 1997-02-25 Yale University Nucleic acids encoding and expression of parathyroid hormone-like peptide
JPH03503844A (ja) * 1988-04-15 1991-08-29 リサーチ　コーポレーシヨン　テクノロジーズ　インコーポレーテツド Ｌａｋ細胞サイトトキシン
DK455789D0 (da) * 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
JP2772062B2 (ja) * 1989-09-26 1998-07-02 株式会社ニッコー 走行玩具の方向変換装置
US5256568A (en) * 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
HUT65827A (en) * 1990-04-02 1994-07-28 Synergen Inc Polypeptides useful in animal treatment against mycoplasma infections
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5503828A (en) * 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
JP2649317B2 (ja) * 1993-10-25 1997-09-03 株式会社キジマ 手袋の製造方法
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
SG119177A1 (en) * 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
JP2001523480A (ja) 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
DE69901321T2 (de) 1998-05-15 2002-12-12 Schering Corp., Kenilworth Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
ATE403728T1 (de) * 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
DK1894944T3 (da) 1998-11-12 2010-10-18 Schering Corp Fremgangsmåder til omdannelse af interferon-isoformer og produkter deraf
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
EP1535622B1 (en) 1999-04-08 2008-12-31 Schering Corporation Melanoma therapy
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ES2306771T3 (es) * 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc Un metodo de terapia celular para tratamiento de tumores.
CN1247258C (zh) 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method
BRPI0415771A (pt) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
GB0420091D0 (en) * 2004-09-10 2004-10-13 Univ Nottingham Trent Medical implant materials
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
GB0514661D0 (en) * 2005-07-16 2005-08-24 Medical Res Council Methods
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2021791A2 (en) * 2006-05-31 2009-02-11 Unilever N.V. Method of screening for compounds that alter skin and/or hair pigmentation
EP2474318A1 (en) * 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
HUE025636T2 (en) 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
RS54204B1 (sr) 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
EP2201953A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US20100249373A1 (en) * 2007-11-27 2010-09-30 Richard Martin Ogborne Screening methods
ME02267B (me) 2008-03-27 2016-04-28 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora nervnih ćelija i mozga
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2010040063A1 (en) * 2008-10-03 2010-04-08 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of hepatitis c infection with metalloporphyrins
ES2342529B1 (es) 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
US20110257368A1 (en) 2008-12-23 2011-10-20 Schering Corporation Purification of recombinantly produced interferon
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
JP5576928B2 (ja) 2009-03-27 2014-08-20 ジェイダブリュ ファーマシューティカル コーポレーション インターフェロン−アルファ及び細胞質残留性細胞膜透過ペプチドを含むＩＦＮ−α融合タンパク質
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
BR112014010295A2 (pt) 2011-10-31 2017-04-18 Gilead Pharmassett Llc métodos e composições para o tratamento de vírus de hepatite c
SG11201402609RA (en) 2011-11-29 2014-06-27 Gilead Pharmasset Llc Compositions and methods for treating hepatitis c virus
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
GB201219678D0 (en) 2012-11-01 2012-12-12 Benf Ab Ketone body inhibitors and uses thereof
US9624527B2 (en) 2013-03-01 2017-04-18 Boehringer Ingelheim Vetmedica, Inc. Quantification of vaccine compositions
WO2014197400A1 (en) 2013-06-04 2014-12-11 Gilead Pharmasset Llc Preventing and treating recurrence of hcv infection after liver transplant
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
EP4012049A3 (en) 2014-04-04 2022-08-24 Crown Bioscience, Inc. (Taicang) Methods for determining responsiveness to mek/erk inhibitors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
IL301919A (en) 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
PE20181583A1 (es) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh Peptido recombinante derivado de la proteina duoxa2
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP4357454A3 (en) 2016-03-16 2024-07-24 Immatics Biotechnologies GmbH Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HRP20221375T1 (hr) 2016-03-16 2023-01-06 Immatics Biotechnologies Gmbh Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka
SG10202110335PA (en) 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
KR20200026898A (ko) 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
EP4761754A2 (en) 2023-08-18 2026-06-24 Immatics Biotechnologies GmbH Peptides displayed by mhc for use in immunotherapy against different types of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699222A (en) * 1958-03-11 1972-10-17 Nat Res Dev Production of viral interfering substances
GB1412591A (en) * 1971-11-30 1975-11-05 Beecham Group Ltd Antiviral ds rna and compositions thereof
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
GB1521032A (en) * 1974-08-08 1978-08-09 Ici Ltd Biological treatment
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
DE2724918A1 (de) * 1977-06-02 1978-12-14 Thomae Gmbh Dr K Gewinnung und reinigung von humaninterferon
ZA782933B (en) * 1977-09-23 1979-05-30 Univ California Purification of nucleotide sequences suitable for expression in bacteria
FR2422956A1 (fr) * 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
JPS5519239A (en) * 1978-07-28 1980-02-09 Green Cross Corp:The Interferon-producing attractant
FI792481A7 (fi) * 1978-08-11 1981-01-01 The Regents Of The Univ Of Enkaroyyttisen proteiinin synteesi mikro-organismia käyttäen.
GB2033905B (en) * 1978-08-21 1982-10-13 Upjohn Co Bacterial preparation of proteins
JPS5561798A (en) * 1978-10-30 1980-05-09 Noda Sangyo Kagaku Kenkyusho Preparation of novel recombination dna
FR2440957A1 (fr) * 1978-11-13 1980-06-06 Pasteur Institut Vecteurs appropries a l'insertion dans leurs genomes de fragments d'adn etrangers, selon l'une quelconque des phases de traduction possibles, et moyens pour leur fabrication
IN150740B (enExample) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4241174A (en) * 1978-11-24 1980-12-23 Hoffmann-La Roche Inc. Interferon assay
FR2444713A1 (fr) * 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
ZA802992B (en) * 1979-06-01 1981-10-28 Univ California Human pre-growth hormone
US4262090A (en) * 1979-06-04 1981-04-14 Cetus Corporation Interferon production

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PROC. JAPAN. ACAD.=1979 *
PROC. NATL. ACAD. SCI.=1979US *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046221A1 (ja) * 2009-10-16 2011-04-21 学校法人立命館 インターフェロン－αモジュレーター
JP5794532B2 (ja) * 2009-10-16 2015-10-14 学校法人立命館 インターフェロン−αモジュレーター

Also Published As

Publication number Publication date
UA13380A (uk) 1997-02-28
JPH0321151B2 (enExample) 1991-03-22
MD431C2 (ro) 1996-07-31
JPS56150100A (en) 1981-11-20
ZA81103B (en) 1982-01-27
JPS62122590A (ja) 1987-06-03
SU1764515A3 (ru) 1992-09-23
IN153751B (enExample) 1984-08-18
US4530901A (en) 1985-07-23

Similar Documents

Publication Publication Date Title
JPH0321151B2 (enExample)
JP2501889B2 (ja) α−インタ−フェロンを含有する薬学的組成物
US7635466B1 (en) DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides
KR920007439B1 (ko) 하이브리드 인간 백혈구 인터페론
KR860001558B1 (ko) 인터페론의 제조방법
JP2558422B2 (ja) インターフェロンをコードする遺伝子
JP2557053B2 (ja) 腫瘍壊死因子の精製、製造および使用法
JP2864996B2 (ja) 免疫学的疾患治療用医薬組成物
JP2612149B2 (ja) α−インターフェロン及びその製造方法
JP2533470B2 (ja) 豚成長ホルモンを生産するためのｄｎａ配列，組換ｄｎａ分子および生産方法
NL8104400A (nl) Microbiele bereiding van menselijk fibroblast interferon.
HU193512B (en) Process for preparing hybride interferones from human erythrocytes
JPH09135690A (ja) 内皮細胞成長因子を発現し得る発現ベクター及びその形質転換細胞
JPH0240080B2 (enExample)
US5026639A (en) Method to improve mRNA translation and use thereof for production of platelet factor-4
WO1990008824A1 (en) Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses
JPS60227694A (ja) ヒト成熟白血球インタフエロンのアミノ酸配列を含むポリペプチドの製造方法
JPS60126299A (ja) 新規インターフェロンγとその製造方法
JPS61149089A (ja) Ｄｎａ塩基配列、ポリペプチド分泌発現ベクター及び形質転換微生物
JPH02195888A (ja) ヒトインターロイキン２活性を有するポリペプチドをコードする遺伝子を含有する組換えｄｎａ体および該組換えｄｎａ体により形質転換された原核生物細胞
KR890001828B1 (ko) 인터페론-α형의 폴리펩티드의 제조방법
KR870000510B1 (ko) 형질전환된 미생물의 제조방법
JPS60232097A (ja) ヒト癌壊死因子ポリペプチドの製造法
KR910009901B1 (ko) 하이브리드 인간 백혈구 인터페론
JPS62151182A (ja) 遺伝子及びその製造方法